Loading...

Purified anti-mouse CD45 Antibody

Pricing & Availability
Clone
30-F11 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5, LCA
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
30-F11_Pure_071608.jpg
BALB/c splenocytes stained with 30-F11 purified, followed by anti-rat IgG FITC
  • 30-F11_Pure_071608.jpg
    BALB/c splenocytes stained with 30-F11 purified, followed by anti-rat IgG FITC
  • 30-F11_Pure_CD45_Antibody_2_102518
    Fresh, frozen mouse spleen was stained with purified CD45 clone 30-F11 conjugated and detected with a FITC CODEX™ oligonucleotide duplex (red). Samples were counterstained with CollagenIV Cy5 (green). Data generated at Akoya Biosciences, Inc. using the CODEX™ technology.
Compare all formats
Cat # Size Price Quantity Check Availability Save
103101 50 µg 29€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103102 500 µg 92€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F, CyTOF® - Verified
IP, CMCD, IHC, WB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Application References
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  2. Li F, et al. 2020. EMBO J. 39:e103205. PubMed
  3. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  4. Tremblay M, et al. 2020. Elife. 9: . PubMed
  5. Malinczak CA, et al. 2021. J Immunol. 206:1315. PubMed
  6. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  7. Ozga AJ, et al. 2022. Immunity. 55:82. PubMed
  8. Moore J, et al. 2022. Cancer Res. 82:365. PubMed
  9. Park JY, et al. 2022. Cell Rep. 38:110219. PubMed
  10. Valet C, et al. 2022. J Clin Invest. 132: . PubMed
  11. Lee NK, et al. 2022. Biomedicines. 10: . PubMed
  12. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  13. Li S, et al. 2022. Nat Commun. 13:7371. PubMed
  14. Abby E, et al. 2023. Nat Genet. 55:232. PubMed
  15. Potempa M, et al. 2022. J Immunol. 208:1742. PubMed
  16. Blomberg E, et al. 2022. Neurooncol Adv. 4:vdac148. PubMed
  17. Murai K, et al. 2022. Nat Commun. 13:6206. PubMed
  18. Hernández-Santana YE, et al. 2020. Life Sci Alliance. 3:00. PubMed
  19. Claveria-Cabello A, et al. 2020. Cancers (Basel). 12:00. PubMed
  20. Davies M, et al. 2017. PLoS Pathogens. 13(6):e1006435. PubMed
  21. Axelrod HD, et al. 2019. Mol Cancer Res. 17:356. PubMed
  22. Schneider H, et al. 2017. J Neurochem. 140:170. PubMed
  23. Shafer MER, et al. 2017. Stem Cell Reports. 1.040277778. PubMed
  24. Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed
  25. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
  26. Tarazi S, et al. 2022. Cell. 185:3290. PubMed
  27. Zhao Q, et al. 2023. Signal Transduct Target Ther. 8:40. PubMed
  28. Wang Y, et al. 2023. J Neuroinflammation. 20:41. PubMed
  29. García Fallit M, et al. 2023. Viruses. 15:. PubMed
  30. Xu J, et al. 2023. Discov Oncol. 14:68. PubMed
  31. Rafaiee R, et al. 2023. Bioimpacts. 13:97. PubMed
  32. Kondo H, et al. 2020. J Biol Chem. 295:1658. PubMed
  33. Fernandes V, et al. 2020. PLoS Pathog. 16:e1008464. PubMed
  34. Nguyen R, et al. 2021. Cancer Immunol Immunother. 70:721. PubMed
  35. Wan Mohd Zawawi WFA, et al. 2021. Sci Rep. 11:10278. PubMed
  36. Maestro S, et al. 2021. Viruses. 13: . PubMed
  37. Reglero-Real N, et al. 2021. Immunity. :. PubMed
  38. Chamberlin T, et al. 2020. Cancer Research. 80(20):4465-4475. PubMed
  39. Li X, et al. 2020. Cell Rep. 31:107765. PubMed
  40. Vitiello GA, et al. 2018. Clin Cancer Res. 24:972. PubMed
  41. Rothchild AC, et al. 2019. Sci Immunol. 4:eaaw6693. PubMed
  42. Widjaja AA, et al. 2019. Gastroenterology. 157:777. PubMed
  43. Heinrich A, et al. 2021. Cell Rep. 37:109885. PubMed
  44. Cooper STE, et al. 2022. Int J Mol Sci. 23:. PubMed
  45. Deppermann C, et al. 2020. J Exp Med. 217:. PubMed
  46. Moon H et al. 2017. Cell stem cell. 21(5):665-678 . PubMed
  47. Rieck M, et al. 2017. Eur J Immunol. 47:677. PubMed
  48. Ajona D, et al. 2017. Cancer Discov. 0.773611111. PubMed
  49. Goel S, et al. 2017. Nature. 548:471. PubMed
  50. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  51. Paulo E, et al. 2018. Sci Rep. 8:11001. PubMed
  52. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  53. Dertschnig S, et al. 2020. J Clin Invest. 130:1896. PubMed
  54. Gao H, et al. 2021. J Virol. :. PubMed
  55. Dienz O, et al. 2020. J Immunol. 204:1521. PubMed
  56. Karhadkar TR, et al. 2021. J Pharmacol Exp Ther. 376:106. PubMed
  57. Liu X, et al. 2020. Nature. . PubMed
  58. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  59. Parlanti P, et al. 2020. Exp Eye Res. 194:107998. PubMed
  60. Lee S, et al. 2020. Cell Host & Microbe. 27(6):937-949. PubMed
  61. Thulasingam S, et al. 2019. Int J Mol Sci. 20. PubMed
  62. Gao J, et al. 2017. Oncol Lett. 14:2954. PubMed
  63. Starossom SC, et al. 2019. Nat Commun. 10:217. PubMed
  64. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  65. Wang G, et al. 2021. Nat Commun. 12:5733. PubMed
  66. Quintana E, et al. 2020. Cancer Res. 80:2889. PubMed
  67. Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed
  68. Paprckova D, et al. 2022. Front Immunol. 13:1009198. PubMed
  69. Schafflick D, et al. 2020. Nat Commun. 247:11. PubMed
  70. Zabaleta N, et al. 2018. Nat Commun. 9:5454. PubMed
  71. Zhu F, et al. 2019. J Immunol. 203:2644. PubMed
  72. Li Y et al. 2019. Endocrinology. 160(4):938-946 . PubMed
  73. Murad JP, et al. 2018. Front Immunol. 1.95. PubMed
  74. Janghorban M, et al. 2022. Cancer Res. 82:885. PubMed
  75. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  76. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
  77. Delgobo M, et al. 2021. Front Immunol. 12:584538. PubMed
  78. Baraibar-Churio A, et al. 2021. Life (Basel). 11:. PubMed
  79. Nam J, et al. 2021. Front Cell Neurosci. 15:640084. PubMed
  80. Park S, et al. 2021. Nat Cell Biol. 23:476. PubMed
  81. Podd B, et al. 2006. J Immunol. 176:6532. PubMed
  82. Hitchcock JR, et al. 2020. FEBS J. 287:250. PubMed
  83. McLeod RL, et al. 2018. Oncotarget. 9:34459. PubMed
  84. Sutton C, et al. 2017. Nat Commun.. 10.1038/s41467-017-02111-0. PubMed
  85. O'Dea KP, et al. 2020. J Extracell Vesicles. 9:1706708. PubMed
  86. Baluk P, et al. 2020. Am J Pathol. 190:2355. PubMed
  87. Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed
  88. Gil-Melgosa L, et al. 2021. Biomedicines. 10:. PubMed
  89. Hagan AS, et al. 2020. Development. 147:00:00. PubMed
  90. Rhee S, et al. 2018. Nat Commun. 9:368. PubMed
  91. Finn J et al. 2019. Cell reports. 26(11):2942-2954 . PubMed
  92. Nolin JD, et al. 2017. JCI Insight. 2:e94929. PubMed
  93. Fiege JK, et al. 2019. PLoS Pathog. 15:e1008077. PubMed
  94. Silvestre-Roig C, et al. 2019. Nature. 569:236. PubMed
  95. Melchor SJ, et al. 2020. Sci Rep. 10:15724. PubMed
  96. He LD, et al. 2021. EMBO Rep. 22:e52196. PubMed
  97. Yim AKY, et al. 2022. Nat Neurosci. 25:238. PubMed
  98. Singh PP, et al. 2021. Ocul Surf. 21:271. PubMed
  99. Cassidy BR, et al. 2020. J Neuroinflammation. 17:259. PubMed
  100. Karhadkar TR, et al. 2021. PLoS One. 16:e0245924. PubMed
  101. Gereke M, et al. 2012. J Vis Exp. 70: 4322. PubMed
  102. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  103. Yoshihara S, et al. 2019. Front Immunol. 0.545833333. PubMed
  104. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  105. Progatzky F, et al. 2021. Nature. 599:125. PubMed
  106. Bruno KA, et al. 2021. Int J Mol Sci. 22:. PubMed
  107. Crawford LB, et al. 2020. Microorganisms. 8:. PubMed
  108. Liu H, et al. 2020. J Immunol. 205:1207. PubMed
  109. Shokirova H, et al. 2021. Sci Rep. 11:8647. PubMed
  110. Brown IK, et al. 2021. PLoS Pathog. 17:e1009602. PubMed
  111. Fu H, et al. 2020. Front Immunol. 11:595813. PubMed
  112. Peralta Ramos JM, et al. 2017. Front Immunol. 1.490277778. PubMed
  113. Ito S, et al. 2020. PLoS One. 15:e0229888. PubMed
  114. Latasa M, et al. 2010. PLoS One. 5:e15690. PubMed
  115. Zhong L, et al. 2022. JCI Insight. 7:. PubMed
  116. Kenswil KJG, et al. 2021. Cell Stem Cell. 28(4):653-670.e11. PubMed
  117. Zareie P, et al. 2017. J Neuroinflammation. 0.630555556. PubMed
  118. Qiu X, et al. 2018. Lab Chip. 18:2776. PubMed
  119. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  120. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
  121. Vu LT, et al. 2019. J Extracell Vesicles. 8:1599680. PubMed
  122. Jones KB et al. 2018. Cell stem cell. 24(1):183-192 . PubMed
  123. Johnson SA, et al. 2021. Eur J Immunol. 51:3228. PubMed
  124. Schuler CF, et al. 2020. Allergy. 75:2279. PubMed
  125. Yoon S, et al. 2020. Antioxidants (Basel). 10:. PubMed
  126. Hashimoto M, et al. 2021. J Neurochem. 156:834. PubMed
  127. Tao H, et al. 2021. Front Immunol. 12:623280. PubMed
  128. Scur M, et al. 2022. Nat Commun. 13:7272. PubMed
  129. Nikolaou K, et al. 2014. EMBO J. 34:430. PubMed
  130. Murai K et al. 2018. Cell stem cell. 23(5):687-699 . PubMed
  131. Morita S et al. 2017. Cell metabolism. 25(4):883-897 . PubMed
  132. Sheppard S, et al. 2018. Front Immunol. 1.630555556. PubMed
  133. Davies CL, et al. 2019. Front Immunol. 10:1048. PubMed
  134. Paharik AE, et al. 2017. Cell Host Microbe. 22:746. PubMed
  135. Lopes N, et al. 2021. Nat Immunol. 22:179. PubMed
  136. Perdigoto AL, et al. 2022. JCI Insight. 7:. PubMed
  137. Ejima R, et al. 2021. Nutrients. 13:. PubMed
  138. Hu CF, et al. 2021. Front Immunol. 12:638381. PubMed
  139. Karhadkar TR, et al. 2020. bioRxiv. . PubMed
  140. Chen Q, et al. 2021. STAR Protocols. 2(1):100241. PubMed
  141. Matsuo K, et al. 2018. J Invest Dermatol. 138:1764. PubMed
  142. Bar O, et al. 2020. Fluids Barriers CNS. 17:27. PubMed
  143. Langer V, et al. 2019. J Clin Invest. 129:4691. PubMed
  144. Poulos MG, et al. 2017. J Clin Invest. 127:4163. PubMed
  145. Janela B, et al. 2019. Immunity. 50:1069. PubMed
  146. Geng T, et al. 2021. J Infect Dis. 223:2186. PubMed
  147. Ishigaki K, et al. 2021. Sci Rep. 11:13958. PubMed
  148. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  149. Somasundaram R, et al. 2021. Blood. 137:3037. PubMed
  150. Prizant H, et al. 2021. Cell Reports. 36:109523. PubMed
  151. Yu W, et al. 2020. J Clin Invest. . PubMed
  152. Baluk P, et al. 2018. Methods Mol Biol. 1846:161. PubMed
  153. Fino KK, et al. 2017. Sci Rep. 5.334722222. PubMed
  154. Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed
  155. Wang Z, et al. 2021. Drug Discov Ther. 14:304. PubMed
  156. Levy BD, et al. 2020. J Allergy Clin Immunol. 145:335. PubMed
  157. Seo SU, et al. 2021. Front Immunol. 12:697162. PubMed
  158. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  159. Chen X, et al. 2019. Methods Mol Biol. 2048:131. PubMed
  160. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  161. Moon H, et al. 2019. Nat Commun. 10:2225. PubMed
  162. Dora D, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1617. PubMed
  163. Fahy N, et al. 2021. Front Immunol. 12:715267. PubMed
  164. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
  165. Cha J, et al. 2015. J Biol Chem. 290:15337. PubMed
  166. Mori Y, et al. 2021. Diabetes and Vascular Disease Research. 18(3):14791641211027324. PubMed
  167. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  168. Tamburini BAJ, et al. 2019. Front Immunol. 10:1036. PubMed
  169. Van Der Zande HJP, et al. 2021. FASEB J. 35:e21331. PubMed
  170. Penny HL, et al. 2021. Int J Mol Sci. 22:. PubMed
  171. Rincón E, et al. 2017. Oncotarget. 8:45415. PubMed
  172. Deng W et al. 2019. Cell reports. 27(6):1755-1768 . PubMed
  173. Parodi B, et al. 2021. Front Immunol. 12:655212. PubMed
  174. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
  175. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  176. Udumula MP, et al. 2021. Mol Metab. 53:101272. PubMed
  177. DeFalco T, et al. 2014. Proc Natl Acad Sci U S A. 111:2384. PubMed
  178. Li Y, et al. 2020. Elife. 9:00. PubMed
  179. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  180. Lee YJ, et al. 2018. Front Microbiol. 9:83. PubMed
  181. Heinrich A, et al. 2020. Cell Rep. 31:107513. PubMed
  182. Van Winkle JA, et al. 2020. J Virol. 94:. PubMed
  183. Maier B, et al. 2020. Nature. 580:257. PubMed
  184. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  185. Aikawa S, et al. 2020. Cell Death Differ. 1489:27. PubMed
  186. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
  187. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
  188. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  189. Stokes KL, et al. 2019. Oncogenesis. 8:24. PubMed
  190. Krenzlin H, et al. 2019. J Clin Invest. 130:1671. PubMed
  191. Winter C, et al. 2018. Cell Metab. 28:175. PubMed
  192. Huppé CA, et al. 2018. Mucosal Immunol. 0.536111111. PubMed
  193. Hassel C, et al. 2021. Front Immunol. 12:754661. PubMed
  194. Obst J, et al. 2020. Front Immunol. 11:579000. PubMed
  195. Dubik M, et al. 2021. Front Neurosci. 15:682451. PubMed
  196. Kästle M, et al. 2020. Cell Commun Signal. 183:18. PubMed
  197. Bernard S, et al. 2018. J Mammary Gland Biol Neoplasia. 23:249. PubMed
  198. Leist SR, et al. 2019. PLoS One. 14:e0220126. PubMed
  199. Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed
  200. Wilke JBH, et al. 2021. Mol Psychiatry. 26:7746. PubMed
  201. Umeda M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  202. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
  203. Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed
  204. He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed
  205. Haber AL, et al. 2017. Nature. 551:333. PubMed
  206. Emrick JJ, et al. 2018. Proc Natl Acad Sci U S A. 115:E12091. PubMed
  207. Seehus CR, et al. 2017. Nat Commun. 8:1900. PubMed
  208. Cédile O, Wlodarczyk A, and Owens T 2017. APMIS.. 10.1111/apm.12740. PubMed
RRID
AB_312966 (BioLegend Cat. No. 103101)
AB_312966 (BioLegend Cat. No. 103102)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD45 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD45 30-F11 FC
Biotin anti-mouse CD45 30-F11 FC
FITC anti-mouse CD45 30-F11 FC
PE anti-mouse CD45 30-F11 FC
PE/Cyanine5 anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 30-F11 FC,IHC-F,CyTOF®,IP,CMCD,IHC,WB
PE/Cyanine7 anti-mouse CD45 30-F11 FC
APC/Cyanine7 anti-mouse CD45 30-F11 FC
Alexa Fluor® 488 anti-mouse CD45 30-F11 FC,SB
Alexa Fluor® 647 anti-mouse CD45 30-F11 FC,ICC,IHC,3D IHC,SB
Pacific Blue™ anti-mouse CD45 30-F11 FC
Alexa Fluor® 700 anti-mouse CD45 30-F11 FC,SB
PerCP/Cyanine5.5 anti-mouse CD45 30-F11 FC
PerCP anti-mouse CD45 30-F11 FC
Alexa Fluor® 594 anti-mouse CD45 30-F11 IHC-F,FC,3D IHC
Brilliant Violet 421™ anti-mouse CD45 30-F11 FC,SB
Brilliant Violet 570™ anti-mouse CD45 30-F11 FC
Brilliant Violet 510™ anti-mouse CD45 30-F11 FC
Brilliant Violet 605™ anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 (Maxpar® Ready) 30-F11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD45 30-F11 FC
Brilliant Violet 711™ anti-mouse CD45 30-F11 FC
Brilliant Violet 785™ anti-mouse CD45 30-F11 FC
Brilliant Violet 650™ anti-mouse CD45 30-F11 FC
APC/Fire™ 750 anti-mouse CD45 30-F11 FC
Brilliant Violet 750™ anti-mouse CD45 30-F11 FC
TotalSeq™-A0096 anti-mouse CD45 30-F11 PG
TotalSeq™-B0096 anti-mouse CD45 30-F11 PG
Ultra-LEAF™ Purified anti-mouse CD45 30-F11 FC,CyTOF®,IP,CMCD,IHC,WB
Spark Blue™ 550 anti-mouse CD45 30-F11 FC
Spark NIR™ 685 anti-mouse CD45 30-F11 FC
TotalSeq™-C0096 anti-mouse CD45 30-F11 PG
Spark YG™ 570 anti-mouse CD45 30-F11 IHC-F
PE/Fire™ 640 anti-mouse CD45 30-F11 FC
APC/Fire™ 810 anti-mouse CD45 30-F11 FC
PE/Fire™ 700 anti-mouse CD45 30-F11 FC
Spark Violet™ 538 anti-mouse CD45 30-F11 FC
Spark YG™ 593 anti-mouse CD45 30-F11 FC
Spark Blue™ 574 anti-mouse CD45 Antibody 30-F11 FC
Spark Blue™ 515 anti-mouse CD45 30-F11 FC
Spark UV™ 387 anti-mouse CD45 30-F11 FC
PE/Fire™ 810 anti-mouse CD45 30-F11 FC
Spark Red™ 718 anti-mouse CD45 (Flexi-Fluor™) 30-F11 FC
Spark PLUS UV395™ anti-mouse CD45 30-F11 FC
Go To Top Version: 3    Revision Date: 10-25-2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account